Maturation-induced Conformational Changes of HIV-1 Capsid Protein and Identification of Two High Affinity Sites for Cyclophilins in the C-terminal Domain*

Michael M. EndrichDagger , Peter Gehrig, and Heinz Gehring§

From the Biochemisches Institut, Universität Zürich, CH-8057 Zürich, Switzerland

    ABSTRACT
Top
Abstract
Introduction
References

Viral incorporation of cyclophilin A (CyPA) during the assembly of human immunodeficiency virus type-1 (HIV-1) is crucial for efficient viral replication. CyPA binds to the previously identified Gly-Pro90 site of the capsid protein p24, but its role remained unclear. Here we report two new interaction sites between cyclophilins and p24. Both are located in the C-terminal domain of p24 around Gly-Pro157 and Gly-Pro224. Peptides corresponding to these regions showed higher affinities (Kd ~ 0.3 µM) for both CyPA and cyclophilin B than the best peptide derived from the Gly-Pro90 site (~8 µM) and thus revealed new sequence motifs flanking Gly-Pro that are important for tight interaction of peptide ligands with cyclophilins. Between CyPA and an immature (unprocessed) form of p24, a Kd of ~8 µM was measured, which corresponded with the Kd of the best of the Gly-Pro90 peptides, indicating an association via this site. Processing of immature p24 by the viral protease, yielding mature p24, elicited a conformational change in its C-terminal domain that was signaled by the covalently attached fluorescence label acrylodan. Consequently, CyPA and cyclophilin B bound with much higher affinities (~0.6 and 0.25 µM) to the new, i.e. maturation-generated sites. Since this domain is essential for p24 oligomerization and capsid cone formation, CyPA bound to the new sites might impair the regularity of the capsid cone and thus facilitate in vivo core disassembly after host infection.

    INTRODUCTION
Top
Abstract
Introduction
References

The cyclophilins represent a ubiquitous family of proteins that are abundant in nearly every cell type and are highly conserved through evolution (1). The main representative of the cyclophilins in mammals is the cytosolic 18-kDa CyPA.1 The closely related CyPB (21 kDa) contains a N-terminal signal sequence that directs this isoform to the endoplasmic reticulum. A characteristic property of cyclophilins is their peptidyl-prolyl cis-trans isomerase (PPIase) activity and their ability to bind cyclosporin A (CsA) that inhibits the PPIase activity. In T cells, the CsA·CyPA complex associates with and inhibits the Ca2+-dependent protein phosphatase calcineurin, resulting in immunosuppression. Natural endogenous ligands of cyclophilins with similar actions as CsA are unknown, and the cellular functions of cyclophilins are still a matter of investigation. A new important property of cyclophilins was found in the human immunodeficiency virus life cycle (2, 3) when a specific association of CyPA with the Gag polyprotein p55gag of HIV-1 (4) was detected.

During or after budding of immature viral particles out of the host cell, the noninfectious virions with a spherical core consisting of Gag proteins are transformed to infectious virions and undergo a dramatic structural rearrangement to an icosahedral shape (5). In the course of this maturation, the pol-encoded HIV protease processes the Gag polyprotein precursor into three major proteins and three smaller polypeptides (6, 7). The capsid protein p24, consisting of a N-terminal and a C-terminal domain, condenses to form the conical core structure surrounding the viral genome. One CyPA molecule per 10 Gag molecules is incorporated into nascent virions, amounting to a total of ~200 molecules/virion (2, 3). CyPB was shown to form in vitro similar complexes with the Gag polyprotein as CyPA but was not found in virions in vivo (2). The interaction with the Gag polyprotein and p24 is mediated by the active site of CyPA and is suppressed in the presence of CsA or SDZ NIM811 (3, 8), a natural nonimmunosuppressive CsA analog that also binds to CyPA and inhibits its PPIase activity. CsA prevents the incorporation of CyPA but inhibits neither the assembly of viral components nor the production of morphologically intact virions (9). However, virions lacking CyPA were found to be considerably reduced in their propagation (10). Single point mutations in the p24 domain of the Gag polyprotein precursor revealed a region with an array of four proline residues to be involved in binding to CyPA (2). Recently, the crystal structure of CyPA complexed with a domain of p24 encompassing the N-terminal two-thirds (residues 1-151) showed binding of CyPA to the proline-rich segment that forms a flexible surface-exposed loop in the mainly alpha -helical p24 fragment (11). The contact region on the p24 loop is restricted to a relatively small area with Gly-Pro90 as the central element buried in the active site of CyPA. This Gly-Pro motif seems to be a prerequisite for stable association. Only if glycine precedes a proline residue is the peptide stretch able to snuggle deeply into the active site of CyPA.

So far, the role of CyPA in the interaction with HIV-1 p24 is not clear. CyPA might act as PPIase and catalyze a cis-trans isomerization in the p24 peptide backbone or might function as chaperone by binding the capsid protein in a conformation prone for propagation, i.e. by destabilizing the capsid cone for postentry disassembly (10). Such an action of CyPA, however, could not be expected to result solely from binding to the site on the loop around Gly-Pro90 in the N-terminal domain. Very recently, it was reported that CyPA disrupts high order p24 complexes, most probably by interfering with p24-p24 interactions (12). As the assembly and disassembly of p24 occur both in the same compartment of the host cell, it remained a puzzle how this CyPA·p24 (Gly-Pro90) interaction should initiate capsid cone disassembly without already affecting viral assembly.

In the present investigation, we have identified two additional CyPA-binding sites in the C-terminal domain of mature p24 capsid protein. Both sites show higher affinities for CyPA and CyPB than the Gly-Pro90 site of p24. These two high affinity binding sites seem to be accessible for CyPA only in the mature p24 capsid protein, i.e. after processing of immature p24 by the HIV-1 protease. A hypothetical model of the function of CyPA in the disassembly of the capsid cone is proposed.

    EXPERIMENTAL PROCEDURES

Materials-- Recombinant immature HIV-1 capsid protein was obtained from D. Sizmann (Hoffmann-La Roche, Basel) in 6 M guanidine HCl and was efficiently refolded by an established method (13, 14) into a correctly folded soluble protein. Folded immature capsid protein was analyzed by CD spectroscopy with regard to secondary structure composition. The obtained CD spectra were comparable ([theta 222]mre: -15,970 millidegrees·M-1·cm2) with that reported for native p24 (14). The correct mass was verified by mass spectrometry, and the protein concentration was determined by quantitative amino acid analysis. The concentration of p24 stock solutions was always kept below 1 mg/ml to avoid aggregation (15). PPIase-active recombinant human CyPA and CyPB were a gift from M. Zurini (Novartis, Basel). Synthetic peptides p(87-101), p(153-172), and p(214-228) were purchased from Neosystem Laboratoire (Strasbourg).

Preparation of Mature p24-- In order to obtain mature p24, folded immature p24 protein was incubated with 1/100 (w/w) of recombinant HIV-1 protease in 30 mM MES, pH 5.5, 200 mM NaCl, 1% (w/w) glycerol, and 1 mM EDTA at 37 °C. The reaction was monitored by analyzing aliquots with SDS-polyacrylamide gel electrophoresis and silver staining (Phast gels, Amersham Pharmacia Biotech). Usually, processing was complete after 4-6 h. The reaction was stopped by adjusting the pH to 8.0. Subsequently, 100 µM EDTA and 5 µM phenylmethanesulfonyl fluoride was added, and the sample was dialyzed against 3 mM Tris-HCl, pH 8.0, 20 mM NaCl to remove cleaved peptides (2.8 and 2.3 kDa) and vacuum-concentrated up to a concentration of <= 1 mg/ml. The concentration of p24 was determined by quantitative amino acid analysis (AminoQuant, Hewlett-Packard) and was in agreement with the concentrations determined by measuring the absorbance at 280 nm (epsilon 280: 33.7 mM-1 cm-1; Ref. 14). An aliquot (20 pmol) of the obtained product was analyzed by liquid chromatography-mass spectrometry (C8-reversed phase HPLC linked to an API III+ electrospray ionization mass spectrometer; PE-Sciex), revealing a molecular mass of 25,578.3 ± 3 Da that was in agreement with the calculated molecular mass of 25,579.5 Da for mature p24. The CD spectrum of processed, i.e. mature, p24 protein was comparable with that reported for native HIV-1 capsid protein (14) and had a mean residue ellipticity of -13,420 millidegrees·M-1·cm2 at 222 nm.

Acrylodan Labeling of p24 and Fluorescence Measurements-- Folded immature p24 (10 µM) was dialyzed against 10 mM HEPES, pH 7.0, and 10 µM dithiothreitol and then incubated with acrylodan (6-acryloyl-2-dimethylaminonaphthalene, 10-fold molar excess over sulfhydryl groups; Molecular Probes Europe BV) in 50 mM HEPES, pH 7.0, 5% (v/v) acetonitrile, and 0.5 M guanidine HCl (a concentration at which native p24 is still stable according to Ref. 14) for 2 h at room temperature in the dark on a rotary device. The reaction mixture subsequently was loaded onto a PD10 gel filtration column (Amersham Pharmacia Biotech) and eluted with 50 mM HEPES, pH 7.0, 5% (v/v) acetonitrile, and 0.2 M guanidine HCl. Protein (p24)-containing fractions were pooled; dialyzed against 2 mM sodium phosphate, pH 7.4, 6 mM NaCl, 6 mM KCl, and 1% (v/v) acetonitrile; and vacuum-concentrated to a concentration still below 1 mg/ml. Mass and UV spectroscopy of the product revealed only monolabeled p24 (most probably at Cys218; see Ref. 16) with 0.3 mol of acrylodan incorporated per mol of p24. In order to obtain acrylodan-labeled mature p24, labeled immature p24 was treated with HIV-1 protease as described before and proven by mass spectroscopy to be correctly processed.

Fluorescence measurements were performed at 25 °C with a spectrofluorimeter (model A1010 equipped with FELIX fluorescence analysis software; Photon Technology International). Excitation was set to 370 nm (3-nm bandwidth), and emission was recorded from 400 to 600 nm (3-nm bandwidth). In order to measure dissociation constants of the complexes between the cyclophilins and mature or immature p24, CyPA or CyPB was added at the indicated concentrations to labeled mature p24 (1.2 or 0.1 µM) or to labeled immature p24 (1.0 µM) in 20 mM sodium phosphate, pH 7.4, 60 mM NaCl, and 60 mM KCl. After each addition, the mixture was incubated until equilibrium had been reached before recording the spectra. In order to calculate Kd values, the change in relative fluorescence was fitted (SigmaPlot, Jandel Corp.) according to the following equation: Delta F = (Delta Fmax/2 × Lt) × [(Lt + Pt + Kd) - {(Lt + Pt + Kd)2 - (4 × Lt × Pt)}0.5], where Delta F is the relative fluorescence change, Delta Fmax is the maximal change, Lt is the total concentration of p24, Pt is the total concentration of CyP, and Kd is the dissociation equilibrium constant. Kd values of independent experiments were within the indicated calculated S.D. values (Table I).

PPIase Activity Measurement-- PPIase activity was measured at 4 °C essentially as recently described (17) with the standard chymotrypsin-coupled assay (18). The assay mixture (0.08 M NaCl, 0.05 M Hepes, pH 8; final volume 200 µl) contained 50 µM of succinyl-Ala-Leu-Pro-Phe-p-nitroanilide (Bachem) and was incubated for at least 10 min at 4 °C. The reaction was started by the addition of chymotrypsin (60 µM) and monitored at lambda  390 nm with a Hewlett-Packard 8450A UV/VIS-spectrophotometer. For competition experiments, recombinant human CyPA (1-5 nM) or CyPB (8-21 nM) was preincubated with or without the corresponding p24 component in the presence of 0.5 µM bovine serum albumin for 1 h at room temperature prior to chymotrypsin addition. In the case of peptide p(214-228), the assay mixture additionally contained 250 µM dithiothreitol. The apparent reaction rate constant kobs was obtained by analyzing the exponential phase (50-500 s) of the curve according to a pseudo-first order reaction. The rate of the spontaneous, uncatalyzed isomerization kuncat (0.0036 ± 0.0002 s-1, at 4 °C) was subtracted from kobs. The percentage inhibition was calculated in relation to the PPIase activity measured in the absence of competitors. In general, each measurement was performed twice, and the average was calculated. Obtained data were fitted according to the equation for competitive inhibition: percentage inhibition = [(100 × It)/(It + IC50)], where It is the total concentration of the competitor and IC50 corresponds to [Ki × (1 + (S/Km))]. Ki is the inhibition constant of the competitor, S is the concentration of the PPIase substrate used in the standard assay, and Km is the Michaelis-Menten constant of the substrate. Since S/Km was approximately <FR><NU>1</NU><DE>20</DE></FR> for the used PPIase substrate, the IC50 values are reflecting Ki values.

Mapping of CyPA-binding Sites on p24-- Fragments of p24 were obtained by incubating recombinant HIV-1 p24 protein with 1/50 (w/w) of 1-chloro-3-tosylamido-7-amino-2-heptanone-pretreated alpha -chymotrypsin (Boehringer Mannheim) in 100 mM Tris-HCl, pH 8.0, 10 mM CaCl2 and 1 M guanidine HCl for 1 h at 37 °C. The reaction was stopped by the addition of phenylmethanesulfonyl fluoride. An aliquot of the digested mixture corresponding to 0.57 nmol (17.4 µg) of original p24 protein was preincubated with or without 0.4 nmol (7.1 µg) of recombinant human CyPA in binding buffer (20 mM Tris-HCl, pH 7.5, 60 mM NaCl, 60 mM KCl, 2 mM CaCl2, and 2 mM MgCl2) for 1 h at room temperature. Subsequently, the reaction mixture (100 µl) was loaded onto a gel filtration column (G25 Superfine, Amersham Pharmacia Biotech; 10 × 85 mm) and eluted with the same buffer containing 10 mM guanidine HCl at 2 ml/min. CyPA-containing fractions (0.5 ml) were adjusted to pH 2 with trifluoroacetic acid and were directly injected onto a C8-reversed phase HPLC column (4.6 × 220 mm; Brownlee). Elution was performed with HPLC buffer A (0.1% trifluoroacetic acid) and a gradient of buffer B (80% acetonitrile, 0.1% trifluoroacetic acid) at 1 ml/min.

Alternatively, recombinant HIV-1 p24 was chemically fragmented by cyanogen bromide in 1 M guanidine HCl and 70% (v/v) trifluoroacetic acid for 20 h at room temperature in the dark. The mixture was lyophilized, resuspended in 5% acetonitrile and 0.1% trifluoroacetic acid, and desalted by reversed phase HPLC. Fractions following the run-through were pooled, vacuum-concentrated, mixed with binding buffer, and incubated with or without CyPA for 1 h at room temperature prior to fast gel filtration chromatography. HPLC-purified extracted CyPA-binding peptides were N-terminally sequenced by automated Edman degradation.

Modification of Synthetic Peptides-- Biotinylation of p(87-101) was carried out by incubating HPLC-purified peptide (in 100 mM Hepes, pH 8.0) with a 1.5-fold molar excess of NHS-Biotin (Sigma), dissolved in Me2SO, for 1 h at room temperature. Excess reagent was trapped by the addition of glycine (2-fold molar excess over NHS-Biotin). The product was purified on a C18-reversed phase HPLC column (3.9 × 150 mm; Waters) and proved to be correct by mass spectrometry and quantitative amino acid analysis.

For acetylation of p(153-172), acetic anhydride (3-fold molar excess, dissolved in 20 mM acetic acid) was added dropwise to a well stirred solution of HPLC-purified peptide in 200 mM sodium phosphate, pH 7.0, on ice. After 30 min, the reaction was stopped by the addition of 2 M hydroxylamine HCl in 0.5 M Tris-HCl, pH 9.6. The product was purified on a C8-reversed phase HPLC column (4.6 × 220 mm; Brownlee) and quantified by amino acid analysis. Fragment ion mass spectrum of the triply charged peptide ion proved the peptide to be exclusively N-terminally acetylated.

    RESULTS

Interaction of CyPA and CyPB with p24-- The presence of a reactive cysteine residue at position 218 of p24 (see Ref. 16 and Fig. 1B) was utilized to introduce the sulfhydryl-specific, environmentally sensitive fluorophore acrylodan (19) into immature p24 (see "Experimental Procedures"). Although formation of an intramolecular disulfide bond between Cys198 and Cys218 has been observed in a truncated p24 encompassing the C-terminal domain (20), such a disulfide bond could not be shown under physiological conditions (16) and is not expected, since the Gag precursor folds and oligomerizes in the reducing environment of the host cell. Acrylodan-labeled immature p24 exhibited maximal fluorescence emission at 498 nm when excited at 370 nm (Fig. 2, C and D). Upon the addition of CyPA, the fluorescence of labeled immature p24 increased in intensity and underwent a blue shift. A dissociation equilibrium constant, Kd, of 8.2 µM (Table I) was calculated from the binding curve (Fig. 2C). In contrast, the fluorescence intensity of labeled immature p24 decreased upon the addition of CyPB (Fig. 2D), and a Kd of 0.9 µM (Table I) was determined. The observed changes in relative fluorescence of labeled immature p24 upon the addition of CyPA or -B were abolished in the presence of CsA, yielding the same fluorescence spectrum as that of unbound immature p24.


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 1.   Scheme of immature HIV-1 capsid protein p24 (A) and amino acid sequence of mature p24 (B). Immature p24 protein consists of the entire p24 capsid protein (residues 1-231, B) flanked N-terminally by a stretch of 25 amino acids (aa) including a His6 tag and C-terminally by 20 amino acids. Similar to the genuine Gag precursor, the N-terminal extension contained 13 specific amino acid residues from the matrix protein p17, whereas the C-terminal extension contained 12 specific residues from p2, a spacer peptide linking the C terminus of p24 to the nucleocapsid protein p7 in the original Gag polyprotein. The cleavage sites recognized by the HIV-1 protease are indicated by arrows. The numbering of the amino acids (B) refers to the mature p24 capsid protein, and the MHR is indicated by shading. The positions of the CyPA-binding fragments I-V (Fig. 4F) within p24 are indicated. The Gly-Pro sequence elements (boldface type) are supposed to be the central CyPA-binding segments of the peptides.


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 2.   Binding of CyPA and CyPB to acrylodan-labeled mature and immature p24. Titration of acrylodan-labeled mature p24 (A and B) as well as labeled immature p24 (C and D) with recombinant human CyPA (A and C) or CyPB (B and D) is shown as the change in relative fluorescence at lambda max. The corresponding fluorescence emission spectra are shown in the insets, and the emission spectra of unbound labeled p24 are indicated by dashed lines. Experimental data were fitted as described under "Experimental Procedures," and the calculated Kd values are summarized in Table I.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Inhibition (Ki) and dissociation equilibrium (Kd) constants of various ligands for cyclophilins

In order to determine the binding characteristics of mature p24, folded immature p24 was correctly processed to mature p24 by the HIV-1 protease, which is also responsible for in vivo processing of the Gag polyprotein. The fluorescence spectra of unliganded acrylodan-labeled mature p24 exhibited maximal emission at 508 nm (Fig. 2, A and B). The fluorescence decreased in intensity upon the addition of CyPA or CyPB without a perceivable shift in lambda max. The Kd values for the CyPA·p24 complex and for the CyPB·p24 were calculated from their respective binding curves (Fig. 2, A and B; Table I). The contribution of the acrylodan label to the binding of p24 to CyP was negligible, as judged by acrylodan-labeled beta -mercaptoethanol that did not show any change in fluorescence intensity upon CyP addition. Again, upon the addition of CsA to the mixture of CyP and p24, the fluorescence spectrum was the same as that of unbound p24. Thus, CsA prevented also the interactions of CyPA and CyPB with labeled mature p24, demonstrating specific binding of labeled p24 in the active site of the cyclophilins.

PPIase Inhibition of CyP by Immature and Mature p24-- To verify the binding properties obtained with the fluorimetric measurements, the inhibitory effect of immature p24 on the PPIase activity of CyPA and CyPB was determined. Immature p24 inhibited the PPIase activity of CyPB (Ki ~ 1.2 µM; Fig. 3) more efficiently than that of CyPA (Ki ~ 8.5 µM). Both Ki values were in excellent agreement with the fluorimetrically determined Kd values.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 3.   Inhibition of the PPIase activity of CyPA and CyPB each by immature (circles) or mature (squares) p24. PPIase activity was measured and calculated as described under "Experimental Procedures." The Ki values of immature p24 are summarized in Table I.

Due to the presence of a His6 tag in immature p24 (Fig. 1), preformed complexes between CyPA and immature p24 could be precipitated with Ni2+-agarose and quantified by densitometric analysis of silver-stained protein bands after SDS-polyacrylamide gel electrophoresis. The calculated apparent dissociation equilibrium constant Kd' of ~19 µM obtained from experiments in which relative low concentrations have been used (0.25 µM p24 and 25 nM to 2.5 µM CyPA) is, as expected (due to a certain dissociation during the procedure), higher (~2-fold) than the Kd and Ki values (Table I). CsA efficiently disrupted the complex (i.e. no CyPA was co-precipitated with immature p24 in the presence of CsA).

Mature p24 was, in contrast to immature p24, susceptible to cleavage by chymotrypsin (used in high concentrations in the standard PPIase activity assay; see "Experimental Procedures"). Most of it was found to be degraded upon analysis by SDS-polyacrylamide gel electrophoresis at the end of the assay. Nevertheless, the PPIase activity of CyPA and CyPB was effectively inhibited at lower concentrations of mature p24 than of immature p24 (Fig. 3). In the case of CyPB, nanomolar concentrations of mature p24 already inhibited part of the PPIase activity of CyPB, but complete inhibition was achieved only at higher concentrations (>10 µM). Therefore, the fluorimetrically determined Kd values seem to reflect the true binding affinities of mature p24 (Table I).

Mapping the CyPA-binding Sites on the p24 Capsid Protein-- The higher affinity of mature p24 as compared with immature p24 with cyclophilins indicates that additional binding sites on p24 become accessible after the precursor is processed by the HIV-1 protease. To map potential CyPA-binding sites on HIV-1 p24, chymotryptic fragments of recombinant p24 were incubated with human CyPA and subjected to a fast size exclusion chromatography (Fig. 4). CyPA-bound peptide segments of p24 co-eluted together with CyPA in the void volume. CyPA-containing fractions were analyzed by reversed-phase HPLC (Fig. 4, D-F). Five CyPA-associated p24 peptides (I-V) were found and identified by mass spectrometry. Peptide I corresponded to the four proline residue-containing sequence 81-117, which encompasses the known Gly-Pro90 site (Fig. 1B). The molecular mass of peptide II mapped to C-terminal fragment 187-227 of mature p24 containing a Gly-Pro sequence element. Peptides III, IV, and V, consisting of residues 152-185, 130-164, and 153-187, respectively, overlap in the major homology region (MHR) of p24 (21), all having two proline residues and a Gly-Pro sequence element.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 4.   Extraction of CyPA-bound p24 peptide fragments by differential gel filtration chromatography. CyPA (A), chymotrypsin-digested p24 (B), and a preincubated mixture (C) of the same amounts of CyPA and chymotrypsin-digested p24 were subjected to a fast gel filtration chromatography, according to "Experimental Procedures." Panels D-F show the corresponding HPLC chromatograms of fraction 5 of the preceding gel filtration. HPLC fractions containing CyPA-bound p24 fragments (F) were subjected to mass spectrometry. The p24 fragments had the following molecular masses: 3980.67 ± 0.65 (I), 4208.60 ± 0.52 (II), 4188.97 ± 0.20 (III), 4239.72 ± 0.22 (IV), and 4303.72 ± 0.35 (V).

To confirm the binding of the proteolytic p24 fragments to CyPA, the same procedure was performed with cyanogen bromide-fragmented p24. Two CyPA-bound peptides were subjected to N-terminal amino acid sequence analysis. The obtained N-terminal sequences YXPTSILDIKQ and TAXQGVG, where X denotes an unidentified amino acid residue, corresponded to cyanogen bromide-generated fragments 145-185 and 216-235, respectively (Fig. 1). Both peptides thus matched the two new binding sites on p24 found with the chymotryptic fragments.

PPIase Inhibition of CyP by p24 Peptide Segments-- Synthetic peptides, corresponding to the chymotryptic fragments with Gly-Pro as the central binding motif, were used to confirm and to define the new CyP-binding sites on p24. The binding properties of these p24 peptides were examined by means of their inhibitory effect on the PPIase activity of CyPA and CyPB. Peptide p(87-101), corresponding to a segment within peptide I, inhibited the PPIase activity of CyPA with a Ki of 170 µM (Table I). The elimination of the positive charge by biotinylation of the N terminus improved the binding 6-fold (Table I), whereas biotin itself did not affect the PPIase activity in concentrations of up to 0.2 mM. Additional amino acid residues preceding His87 contributed to better binding of peptide I (Ki of 8.3 µM), which encompasses the entire sequence of the surface-exposed loop between helices 4 and 5 of p24 (Fig. 5A; Table I). Peptide I was purified from the chymotrypsin digest of p24 in amounts sufficient for the inhibition studies.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 5.   Inhibition of PPIase activity by p24 peptides corresponding to the deduced CyPA-binding sites. Either CyPA (filled circles) or CyPB (hollow circles) was preincubated with the indicated concentrations of peptide I (A) representing the entire surface-exposed loop between helices 4 and 5 of p24 (Figs. 1B and 4F), N-acetylated peptide p(153-172) (B) representing the major homology region, or peptide p(214-228) (C) from the C terminus of p24. PPIase activity was measured and calculated as described under "Experimental Procedures." The determined Ki values are summarized in Table I.

The N-acetylated synthetic MHR peptide p(153-172) was shown to inhibit the PPIase activity of CyPA and CyPB already at lower concentrations (Fig. 5B) compared with peptide I (Fig. 5A). The experimental data displayed a complex inhibition behavior due to the fragmentation of the Phe-containing MHR peptide during the time of activity measurement by chymotrypsin, which was present in high concentrations in the standard PPIase assay. Apparently, the inhibition curves reflect a heterogeneous and dynamic inhibition of the PPIase activities by a mixture of truncated MHR peptides, whose individual affinities will be lower than that of the original MHR peptide. Thus, only IC50 values of 12 and 27 µM for CyPA and CyPB, respectively, could be determined. The effective concentrations of intact MHR peptide must be much lower than the indicated concentrations (Fig. 5B). The observed partial inhibition at initial concentrations of the peptide below 0.1 µM, however, shows that intact MHR peptides are able to bind to the active site of both cyclophilins at very low concentrations. This suggests the MHR peptide to be a high affinity ligand for CyPA (Kd <=  1 µM) if residues following Phe161 are not cleaved off by chymotrypsin. The fact that complexes of CyPA with chymotryptic or cyanogen bromide fragments of p24 encompassing the MHR could be isolated (Fig. 4F) corroborates this conclusion.

Peptide p(214-228), corresponding to the C-terminal binding site on p24, displayed a homogeneous competitive inhibition of PPIase activity and seems to have the highest affinity toward CyPA (Ki of 0.35 µM) and CyPB (Ki of 0.29 µM) among the three identified p24 binding sites (Fig. 5C; Table I). The presence of a cysteine residue (Cys218) allowed us to label this peptide with acrylodan (for details, see Ref. 22) and to measure its interactions with CyPA and CyPB. The calculated Kd values 0.40 and 0.29 µM, respectively, corresponded excellently with the Ki values determined by the competitive PPIase assay (Table I), emphasizing the equivalence of the different methods applied.

    DISCUSSION

The results presented in this study indicate that HIV-1 capsid protein p24 contains, in total, three sites that are able to interact specifically with CyPA and CyPB. One binding site, the low affinity site, matches to the loop around Gly-Pro90, which has been previously proposed on the basis of mutation experiments (2) and verified by crystallographic analysis of the complex of CyPA with CA151, a truncated p24 encompassing the N-terminal domain (11). The reported Kd of ~16 µM for the CA151·CypA complex (23) is comparable with the present value of 8 µM for peptide I (Table I). The two additional binding sites, one within the MHR and another at the very C terminus of mature p24, show higher affinities and were not known so far. Both of them contain the Gly-Pro motif, which was shown to be the central element and a prerequisite for binding to CyPA (11, 24). A homology among the Gly-Pro adjacent amino acid residues of the three binding sites is not evident. The more than 20-fold higher affinity of CyPA for the C-terminal peptide than for the Gly-Pro90 peptides might be attributed to the presence of an additional Gly and of positive charged amino acid residues in the segment following Gly-Pro224 (Table I). A homologous peptide containing the sequence SIHIGPGRAF and which fulfills the above criteria was shown to bind to CyPA with a Kd of 0.33 µM and to CyPB with a Kd of 0.19 µM (22). Basic residues, C-terminal of Gly-Pro, are also found in the MHR peptide p(153-172), which binds more tightly to the cyclophilins than the Gly-Pro90 peptides if the residues following Phe161 are still present (see "Results"). The crystallographic studies of the low affinity binding site revealed that the Gly-Pro90 adjacent residues predominantly interact with CyPA by their backbone atoms (11, 25). The present results with the two high affinity binding sites, however, demonstrate significant contributions of GP-flanking side chains to the binding to cyclophilins.

Whereas complex formation of CyPA and CyPB with the p24 peptides was comparable, substantial differences in affinity were found with mature and immature p24. The immature protein form has, like the unprocessed Gag polyprotein precursor, an N- and C-terminal extension (Fig. 1) that seems to be important for proper assembly of the initial virion core shell (26-29) and thus probably also for its proper conformation. The binding affinity of CyPA for immature p24 (Kd ~ 8.3 µM) is identical with that for the Gly-Pro90 site. These results suggest that the binding of CyPA to immature p24 occurs through the Gly-Pro90 site, as proposed previously (2, 11, 23, 30). In contrast to CyPA, the affinity of CyPB for immature p24 is 8-fold higher (Kd ~1 µM) indicating a complex formation via a different binding site on p24, most likely the MHR. Evidence for a different binding site for CyPB on immature (i.e. unprocessed) p24, compared with CyPA, is given by the different fluorescence changes upon the addition of the cyclophilins (Fig. 2, C and D) but also by the observation that two Gag mutants, which had either Gly89 or Pro90 exchanged for Ala, lost their ability to bind CyPA but were still able to associate with CyPB (2, 9). The stronger interaction of the Gag polyprotein with CyPB than with CyPA explains why 10-fold higher concentrations of CsA are needed to disrupt this complex (4).

Processing the immature p24 protein to the mature p24 form of the capsid protein by HIV-1 protease increased the affinity 13- and 4-fold for CyPA and CyPB, respectively. The agreement of the Kd values for mature p24 with that for peptide p(214-228) suggests the C-terminal binding site to be responsible for the high affinity interaction of the mature p24 form with the cyclophilins and not the Gly-Pro90 site. The fluorescence intensity of acrylodan-labeled immature p24 increased upon CyPA binding, resulting in a Kd of 8.2 µM, whereas that of labeled mature p24, carrying the environmentally sensitive label at the same site, decreased upon the addition of already low concentrations of CyPA. This observation indicates different primary interaction sites of immature and mature p24 with CyPA and thus different conformations of the two p24 forms. The induced accessibility of the C-terminal binding site(s) on maturation has to be caused by a conformational rearrangement in the C-terminal domain of the capsid protein or by the loss of N-terminal and C-terminal extensions of immature p24. The observed processing-induced change in the fluorescence spectrum of unliganded p24 (Fig. 2, A and B versus C and D) indicates a structural rearrangement, particularly in the C-terminal domain where the label is attached (see "Experimental Procedures"). A maturation-induced accessibility of the MHR-located binding site for CyPA is also indicated by the comparable estimated Kd for the MHR peptide p(153-172) (see discussion under "Results") and for the mature p24 protein. The recently reported structure of the C-terminal domain of p24 (20) suggests that both high affinity binding sites are accessible for CyPA. Structural data of the C-terminal 11 amino acids, including Gly223-Pro224, however, could not be collected, suggesting a rather flexible structure. Thus, this part of p24 is very likely to be as well suited as the free peptide to fit into the active site of CyPA and CyPB as predicted from the present study.

That the high affinity interaction of CypA with p24 was not detected in previous isothermal titration experiments with directly expressed mature recombinant p24 (23) might well be due to the different experimental conditions. The fluorescence method applied in the present study allowed measurements at 50-500-fold lower concentrations of p24, thus avoiding aggregations of p24 that occur at higher concentrations (15) and that could have disturbed the accessibility of the high affinity sites in isothermal titration experiments. Differences in conformations due to different manufacturing methods of the mature p24 might be another reason. In the present study, mature p24 was prepared, similar as in vivo, from a folded precursor that was processed as in vivo by the HIV-1 protease.

Role of CyPA-p24 Interaction-- Growing evidence emphasizes the role of different cyclophilin-binding sites on a single p24 molecule. During viral assembly of the Gag polyprotein precursors, the essential incorporation of CyPA into the virion is mediated by its binding to the Gly-Pro90 site, which, at this stage, is according to the present results the only accessible CyPA binding site. The ratio of only one incorporated CyPA to 10 Gag polyproteins (2, 3) might reflect the moderate binding affinity, as has been already discussed (23). A function of virion-incorporated CyPA in the viral assembly process has been ruled out (9); rather, a role in capsid cone disassembly after viral infection, possibly by weakening the capsid cone already prior to viral host penetration, has been postulated (10). The present results suggest that virus-incorporated CyPA bound to the Gly-Pro90 site might be attracted in the course of the maturation process by the newly generated higher affinity binding sites in the C-terminal domain of p24, which is important for p24 oligomerization (Fig. 6). Indeed, CyPA disrupts high order p24 complexes (12) but obviously allows assembly of the C-terminal domain-missing capsid protein (CA151) into continuous planar strips even if it is bound to the Gly-Pro90 site (11). The function of C-terminal domain-bound CyPA could thus be to promote destabilization of the capsid cone structure. This hypothesis would be in agreement with the observation that propagation of virions generated in the presence of CsA, which abolishes CyPA incorporation, is blocked after infection (9). Obviously, the absence of CyPA in the virus cannot be compensated by abundant cytosolic CyPA after infection of a target cell (3, 9). If the Gly-Pro90 site would indeed remain the target of CyPA action, cytosolic CyPA should be able to substitute CyPA deficiency after viral entry, due to the outside exposure and accessibility of this loop on the capsid cone. In contrast, the C-terminal binding sites in the mature capsid cone might be accessible to cellular cyclophilins after infection only, if the regularity and stability of the structure of the capsid cone is impaired, by virus-intrinsic CyPA molecules. In some cases, destabilizing mutations in p24 (31, 32) might dispense the virus from incorporation of CyPA. Intracellular cyclophilins and possibly other components might then facilitate complete disassembly. If the capsid cone is not destabilized, initiation of the disassembly process will be difficult but might be possible in cells with high concentrations of intracellular cyclophilins, as was recently observed (33).


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 6.   Model of CyPA action on the capsid cone architecture. The capsid protein p24 of HIV-1 is supposed to dimerize by interactions between the N-terminal domains (N) of two p24 molecules and to oligomerize to higher order structures by aggregation of p24 dimers through their C-terminal domains (C) containing the MHR (20, 34). After processing of the Gag polyprotein and due to conformational changes, high affinity binding sites for cyclophilins are generated in the C-terminal domain of p24 additionally to the low affinity Gly-Pro90 site in the N-terminal domain. Cyclophilin interaction in the C-terminal domain is expected to destabilize the capsid cone for postinfection disassembly.

In conclusion, the present finding of two high affinity binding sites for CyPA and CyPB within the C-terminal domain of HIV-1 p24 revealed not only sequence motifs of Gly-Pro flanking regions that are important for tight binding of peptide ligands to the cyclophilins but also a feasible model for the cyclophilin-capsid protein interactions in the HIV-1 life cycle (Fig. 6). CyPA is incorporated into the virions by binding to the Gly-Pro90 site (N-terminal domain of p24) of the Gag polyprotein precursor. Processing of Gag proteins by the viral protease induces a conformational change and generates high affinity binding sites in the C-terminal domain of p24 that will attract CyPA, and this complex could destabilize the capsid cone for disassembly. In view of the observed binding of CyPA to a site in the MHR of p24, which is well conserved in HIV-1, HIV-2, and other lentiviruses as well as in oncoviruses, intracellular cyclophilins might well be the postulated highly conserved binding partner for this region (20).

    ACKNOWLEDGEMENTS

We thank Dorothea Sizmann (Hoffmann-La Roche, Basel) for providing recombinant HIV-1 capsid protein p24 and Neil Birchler for performing amino acid sequence analyses. Recombinant human CyPA, CyPB, and CsA were kindly provided by Mauro Zurini (Novartis, Basel).

    FOOTNOTES

* This work was supported in part by Swiss National Science Foundation Grant 31-45940.95 and AIDS-Komission Grant 438+-50297.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Present address: GlaxoWellcome AG, Clinical Research, CH-3322 Schönbühl, Switzerland.

§ To whom correspondence should be addressed: Inst. of Biochemistry, University of Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland. Tel.: 41-1-635-5572; Fax: 41-1-635-6805; E-mail: gehring{at}bioc.unizh.ch.

    ABBREVIATIONS

The abbreviations used are: CyP, CyPA, and CyPB, cyclophilin, cyclophilin A, and cyclophilin B, respectively; CA, HIV-1 capsid protein p24; CsA, cyclosporin A; HIV-1, human immunodeficiency virus type-1; HPLC, high performance liquid chromatography; MHR, major homology region; PPIase, peptidyl-prolyl cis-trans isomerase; MES, 2-(N-morpholino)ethanesulfonic acid.

    REFERENCES
Top
Abstract
Introduction
References
  1. Galat, A., and Metcalfe, S. M. (1995) Prog. Biophys. Mol. Biol. 63, 67-118[CrossRef][Medline] [Order article via Infotrieve]
  2. Franke, E. K., Yuan, H. E. H., and Luban, J. (1994) Nature 372, 359-362[CrossRef][Medline] [Order article via Infotrieve]
  3. Thali, M., Bukovsky, A., Kondo, E., Rosenwirth, B., Walsh, C. T., Sodroski, J., and Göttlinger, H. G. (1994) Nature 372, 363-365[CrossRef][Medline] [Order article via Infotrieve]
  4. Luban, J., Bossolt, K. L., Franke, E. K., Kalpana, G. V., and Goff, S. P. (1993) Cell 73, 1067-1078[Medline] [Order article via Infotrieve]
  5. Nermut, M. V., Grief, C., and Hockley, D. J. (1993) AIDS Res. Hum. Retroviruses 9, 929-938[Medline] [Order article via Infotrieve]
  6. Henderson, L. E., Bowers, M. A., Sowder, R. C., II, Serabyn, S. A., Johnson, D. G., Bess, J. W., Jr., Arthur, L. O., Bryant, D. K., and Fenselau, C. (1992) J. Virol. 66, 1856-1865[Abstract]
  7. Jones, I., and Stuart, D. (1996) Nature Struct. Biol. 3, 818-820[Medline] [Order article via Infotrieve]
  8. Billich, A., Hammerschmid, F., Peichl, P., Wenger, R., Zenke, G., Quesniaux, V., and Rosenwirth, B. (1995) J. Virol. 69, 2451-2461[Abstract]
  9. Braaten, D., Franke, E. K., and Luban, J. (1996) J. Virol. 70, 3551-3560[Abstract]
  10. Luban, J. (1996) Cell 87, 1157-1159[Medline] [Order article via Infotrieve]
  11. Gamble, T. R., Vajdos, F. F., Yoo, S., Worthylake, D. K., Houseweart, M., Sundquist, W. I., and Hill, C. P. (1996) Cell 87, 1285-1294[Medline] [Order article via Infotrieve]
  12. Agresta, B. E., and Carter, C. A. (1997) J. Virol. 71, 6921-6927[Abstract]
  13. Hausdorf, G., Gewiess, A., Wray, V., and Porstmann, T. (1994) J. Virol. Methods 50, 1-9[Medline] [Order article via Infotrieve]
  14. Misselwitz, R., Hausdorf, G., Welfle, K., Höhne, W. E., and Welfle, H. (1995) Biochim. Biophys. Acta 1250, 9-18[Medline] [Order article via Infotrieve]
  15. Ehrlich, L. S., Agresta, B. E., and Carter, C. A. (1992) J. Virol. 66, 4874-4883[Abstract]
  16. McDermott, J., Farrell, L., Ross, R., and Barklis, E. (1996) J. Virol. 70, 5106-5114[Abstract]
  17. Endrich, M. M., Grossenbacher, D., Geistlich, A., and Gehring, H. (1996) Biol. Cell 88, 15-22[CrossRef][Medline] [Order article via Infotrieve]
  18. Harrison, R. K., and Stein, R. K. (1990) Biochemistry 29, 3813-3816[Medline] [Order article via Infotrieve]
  19. Schmid, D., Baici, A., Gehring, H., and Christen, P. (1994) Science 263, 971-973[Medline] [Order article via Infotrieve]
  20. Gamble, T. R., Yoo, S., Vajdos, F. F., von Schwedler, U. K., Worthylake, D. K., Wang, H., McCutcheon, J. P., Sundquist, W. I., and Hill, C. P. (1997) Science 278, 849-853[Abstract/Free Full Text]
  21. Wills, J. W., and Craven, R. C. (1991) AIDS 5, 639-654[Medline] [Order article via Infotrieve]
  22. Endrich, M. M., and Gehring, H. (1998) Eur. J. Biochem. 252, 441-446[Abstract]
  23. Yoo, S., Myszka, D. G., Yeh, C. Y., McMurray, M., Hill, C. P., and Sundquist, W. I. (1997) J. Mol. Biol. 269, 780-795[CrossRef][Medline] [Order article via Infotrieve]
  24. Zhao, Y., Chen, Y., Schutkowski, M., Fischer, G., and Ke, H. (1997) Structure 5, 139-146[Abstract]
  25. Vajdos, F. E., Yoo, S. H., Houseweart, M., Sundquist, W. I., and Hill, C. P. (1997) Protein Science 6, 2297-2307[Abstract/Free Full Text]
  26. Gross, I., Hohenberg, H., Huckhagel, C., and Krausslich, H. G. (1998) J. Virol. 72, 4798-4810[Abstract/Free Full Text]
  27. Accola, M. A., Höglund, S., and Göttlinger, H. G. (1998) J. Virol. 72, 2072-2078[Abstract/Free Full Text]
  28. Vonschwedler, U. K., Stemmler, T. L., Klishko, V. Y., Li, S., Albertine, K. H., Davis, D. R., and Sundquist, W. I. (1998) EMBO J. 17, 1555-1568[Abstract/Free Full Text]
  29. Gay, B., Tournier, J., Chazal, N., Carriere, C., and Boulanger, P. (1998) Virology 247, 160-169[CrossRef][Medline] [Order article via Infotrieve]
  30. Braaten, D., Franke, E. K., and Luban, J. (1996) J. Virol. 70, 4220-4227[Abstract]
  31. Braaten, D., Aberham, C., Franke, E. K., Yin, L., Phares, W., and Luban, J. (1996) J. Virol. 70, 5170-5176[Abstract]
  32. Gitti, R. K., Lee, B. M., Walker, J., Summers, M. F., Yoo, S., and Sundquist, W. I. (1996) Science 273, 231-235[Abstract]
  33. Ackerson, B., Rey, O., Canon, J., and Krogstad, P. (1998) J. Virol. 72, 303-308[Abstract/Free Full Text]
  34. Momany, C., Kovari, L. C., Prongay, A. J., Keller, W., Gitti, R. K., Lee, B. M., Gorbalenya, E., Tong, L., McClure, J., Ehrlich, L. S., Summers, M. F., Carter, C., and Rossmann, M. G. (1996) Nat. Struct. Biol. 3, 763-770[Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.